ezetimibe has been researched along with tacrolimus in 8 studies
| Studies (ezetimibe) | Trials (ezetimibe) | Recent Studies (post-2010) (ezetimibe) | Studies (tacrolimus) | Trials (tacrolimus) | Recent Studies (post-2010) (tacrolimus) |
|---|---|---|---|---|---|
| 2,484 | 563 | 1,465 | 17,757 | 2,319 | 6,661 |
| Protein | Taxonomy | ezetimibe (IC50) | tacrolimus (IC50) |
|---|---|---|---|
| Bile salt export pump | Homo sapiens (human) | 7.18 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.58 | |
| Cytochrome P450 3A5 | Homo sapiens (human) | 0.385 | |
| Serine/threonine-protein kinase mTOR | Homo sapiens (human) | 0.0021 | |
| Peptidyl-prolyl cis-trans isomerase FKBP1A | Homo sapiens (human) | 0.2547 | |
| Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform | Homo sapiens (human) | 0.0148 | |
| Splicing factor 3B subunit 3 | Homo sapiens (human) | 0.0123 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 3.3 | |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 3.7 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, TK; Ensom, MH; Kiang, TK | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Heemann, U; Kohnle, M; Kribben, A; Philipp, T; Pietruck, F; Witzke, O | 1 |
| Engel, A; Hanke, U; Keiser, M; Lütjohann, D; Modess, C; Nassif, A; Oswald, S; Runge, D; Siegmund, W; Ulrich, A; Weitschies, W | 1 |
| Bašić-Jukić, N; Sabljić, Z | 1 |
2 review(s) available for ezetimibe and tacrolimus
| Article | Year |
|---|---|
UDP-glucuronosyltransferases and clinical drug-drug interactions.
Topics: Clinical Trials as Topic; Drug Interactions; Enzyme Activation; Enzyme Induction; Glucuronides; Glucuronosyltransferase; Humans; Pharmaceutical Preparations; Pharmacogenetics; Polymorphism, Genetic | 2005 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for ezetimibe and tacrolimus
| Article | Year |
|---|---|
Ezetimibe for the treatment of uncontrolled hypercholesterolemia in patients with high-dose statin therapy after renal transplantation.
Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; Cholesterol; Cyclosporine; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Kidney Transplantation; Liver; Male; Middle Aged; Muscle, Skeletal; Pravastatin; Simvastatin; Tacrolimus | 2006 |
Drug interactions between the immunosuppressant tacrolimus and the cholesterol absorption inhibitor ezetimibe in healthy volunteers.
Topics: Administration, Oral; Adult; Animals; Anticholesteremic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azetidines; Cell Line; Cross-Over Studies; Dogs; Drug Interactions; Ezetimibe; Female; Glucuronosyltransferase; Humans; Immunosuppressive Agents; In Vitro Techniques; Male; Tacrolimus; Young Adult | 2011 |
4 other study(ies) available for ezetimibe and tacrolimus
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
New drugs.
Topics: Administration, Topical; Adult; Anti-Bacterial Agents; Anticholesteremic Agents; Azetidines; Child; Drug Therapy; Ezetimibe; Humans; Immunosuppressive Agents; Ketolides; Pharmaceutical Preparations; Tacrolimus | 2004 |
Toxic myopathy and liver damage caused by concomitant therapy with remdesivir, atorvastatin, ezetimibe, and tacrolimus in a renal transplant patient with recently treated SARS-CoV-2 induced pneumonia: A case report.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Atorvastatin; COVID-19 Drug Treatment; Ezetimibe; Humans; Kidney Transplantation; Liver; Myotoxicity; Pneumonia; SARS-CoV-2; Tacrolimus | 2022 |